Literature DB >> 3934624

Ocular manifestations in Kniest syndrome, Smith-Lemli-Opitz syndrome, Hallermann-Streiff-François syndrome, Rubinstein-Taybi syndrome and median cleft face syndrome.

A M Bardelli, G Lasorella, L Barberi, M Vanni.   

Abstract

In the pathology of malformations it is only in very few cases possible to identify a complete syndromal picture; the authors present some multimalformative syndromes, observed in the past few years at the Department of Pediatric Ophthalmology of the University of Siena. The ocular findings are reported and discussed in relation with the general features in order to make a correct diagnosis.

Entities:  

Mesh:

Year:  1985        PMID: 3934624

Source DB:  PubMed          Journal:  Ophthalmic Paediatr Genet        ISSN: 0167-6784


  6 in total

1.  Infantile glaucoma in Rubinstein-Taybi syndrome.

Authors:  J DaCosta; J Brookes
Journal:  Eye (Lond)       Date:  2012-06-22       Impact factor: 3.775

Review 2.  The role of cholesterol in rod outer segment membranes.

Authors:  Arlene D Albert; Kathleen Boesze-Battaglia
Journal:  Prog Lipid Res       Date:  2005-03-09       Impact factor: 16.195

Review 3.  The Smith-Lemli-Opitz syndrome.

Authors:  R I Kelley; R C Hennekam
Journal:  J Med Genet       Date:  2000-05       Impact factor: 6.318

4.  Hallermann-Streiff syndrome diagnosed in the seventh decade of life.

Authors:  Ayaka Shimada; Yuji Takayanagi; Sho Ichioka; Akiko Ishida; Masaki Tanito
Journal:  Am J Ophthalmol Case Rep       Date:  2022-05-25

5.  Retinal degeneration in a rodent model of Smith-Lemli-Opitz syndrome: electrophysiologic, biochemical, and morphologic features.

Authors:  Steven J Fliesler; Neal S Peachey; Michael J Richards; Barbara A Nagel; Dana K Vaughan
Journal:  Arch Ophthalmol       Date:  2004-08

6.  Significant ocular findings are a feature of heritable bone dysplasias resulting from defects in type II collagen.

Authors:  Sarah P Meredith; Allan J Richards; Philip Bearcroft; Arabella V Pouson; Martin P Snead
Journal:  Br J Ophthalmol       Date:  2007-03-08       Impact factor: 4.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.